Perindopril and cardiovascular disease – 25 years of success in cardiology
Authors:
J. Vítovec 1; J. Špinar 2; L. Špinarová 1
Authors‘ workplace:
I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně
2 Interní kardiologická klinika LF MU a FN Brno
1
Published in:
Kardiol Rev Int Med 2018, 20(3): 218-222
Perindopril je dlouhodobě působící lipofilní inhibitor angiotenzin konvertujícího enzymu s jednodenním dávkováním a vysokou afinitou ke tkáňovému konvertujícímu enzymu. Jeho bezpečnost, účinnost a velmi dobrá tolerance je ověřena u hypertenze, srdečního selhání, dokumentované ischemické choroby srdeční, stavů po cévní mozkové příhodě či infarktu myokardu či prevenci kardiovaskulárního postižení. Perindopril je též součástí řady fixních kombinací, které zlepšují compliance nemocného k léčbě a zvyšují účinky léčby kardiovaskulárních onemocnění.
Overview
Perindopril is a long-acting lipophilic angiotensin-converting enzyme inhibitor effective in a once-daily dosage and showing a high affinity to tissue-converting enzyme. Its safety, efficacy and very good tolerance have been proved in hypertension, heart failure, coronary heart disease and conditions resulting from cerebrovascular accident or myocardial infarction or in the prevention of cardiovascular disease. Perindopril is integral to many fixed combinations, improving patient compliance and cardiovascular disease outcomes.
Key words:
Perindopril – ACE inhibitor – hypertension – heart failure – coronary heart disease – cerebrovascular accident – diabetes mellitus – fixed combination
Sources
1. Špinar J, Vítovec J. Perindoprilum. Remedia 2005; 15(2): 121– 135.
2. Remko M, Remková A. Perindopril arginin: nová sůl inhibitoru ACE perindoprilu a její přínos. Remedia 2007; 17(4): 421– 424.
3. Dinicolantonio JJ, Lavie CJ, O’Keefe JH. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. Postgrad Med 2013; 125(4): 154– 168. doi: 10.3810/ pgm.2013.07.2687.
4. Widimský J jr, Filipovský J, Ceral J et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. Hypertenze & kardiovaskulární prevence 2018; 7 (Suppl): 1– 22.
5. Williams B, Mancia G, Spiering W et al. 2018 ESC/ ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; doi: 10.1093/ eurheartj/ ehy339.
6. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regiment of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure LOwering Arm (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet 2005; 366(9489): 895– 906. doi: 10.1016/ S0140-6736(05)67185-1
7. Speirs C, Wagniart F, Poggi L. Perindopril postmarketing surveillance: a 12 month study in 47 351 hypertensive patients. Br J Clin Pharmacol 1998; 46(1): 63– 70.
8. Špinar J, Hradec J, Špinarová L et al. Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Cor Vasa 2016; 58(5): e530– e568.
9. Squire IB, Violet I, Chiche M et al. Acceptability of long-term perindopril in the treatment of mild to moderate chronic heart failure. Clin Cardiol 1996; 19: 9– 15.
10. Lechat P, Garnham SP, Desche P et al. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J 1993; 126(3 Pt 2): 798– 806.
11. MacFayden RJ, Lees KR, Reid JL. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure. Br Heart J 1991; 66(3): 206– 211.
12. Vítovec J, Špinar J. First dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Eur J Heart Failure 2000; 2(3): 299– 304.
13. Cleland JG, Tendera H, Adamus J et al. PEP-CHF Investigators. The perindopril in elderly people of chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27(19): 2338– 2345. doi: 10.1093/ eurheartj/ ehl250.
14. Widimský J. Léčba diastolického srdečího selhání. Výsledky studie PEP-CHF. Cor Vasa 2006; 48(11): 403– 407.
15. Fox KM. The EURopean Trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782– 788.
16. Widimský P. Studie EUROPA: Úspěch perindoprilu a české kardiologie. Cor Vasa 2004; 46: 7– 8.
17. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood pressure-lowering regimen among 6 105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358(9287): 1033– 1041. doi: 10.1016/ S0140-6736(01)06178-5.
18. PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24(5): 475– 484.
19. Fressinaud P, Berrut G, Gallois H. Antihypertensive activity and acceptability based on clinical and laboratory paremeters of perindopril: chief results in 23,460 mild to moderate hypertension patients treated for 6 months in general practice. Ann Cardiol Angeiol Paris 1993; 42(1): 51– 59.
20. Kvetny J, Gregersen G, Pedersen RS. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type I diabetes mellitus. QJM 2001; 94(2): 89– 94.
21. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590); 829– 840. doi: 10.1016/ S0140-6736(07)61303-8.
22. Szabó M. Studie ADVANCE – větev léčby glykémie: význam intenzivní intervence hyperglykémie pro rozvoj vaskulárních komplikací diabetu. Med Pro Praxi 2009; 6(1): 17– 21.
23. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Medicine 2009; 122(3): 290– 300. doi: 10.1016/ j.amjmed.2008.09.038.
24. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120(8): 713– 719. doi: 10.1016/ j.amjmed.2006.08.033.
25. Rosolová H. Moderní kombinovaná terapie hypertenze, fixní kombinace perindoprilu a indapamidu. Remedia 2011; 21(2): 205– 208.
26. Vítovec J, Špinar J. Perindopril/ indapamid – fixní kombinace. Remedia 2007; 17(3): 247– 257.
27. Špinar J, Vítovec J, Špinarová L. Fixní kombinační léčba hypertenze. Kardiol Rev Int Med 2016, 18(2): 85– 93.
28. Ferrari R. Optimizing the treatmentof hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/ amlodipine. Curr Med Res Opin 2008; 24(12): 3543– 3557. doi: 10.1185/ 03007990802576302.
29. Bertrand ME. Perindopril/ amlodipine combination: an optimal synergy for cardiovascular protection. Eur Heart J Suppl 2009; 11 (Suppl E): E22– E25. doi: 10.1093/ eurheartj/ sup019.
30. Špinar J, Vítovec J. COSYREL – lék pro pacienty s ischemickou chorobou srdeční a srdečním selháním. Kardiol Rev Int Med 2017; 19(1): 62– 67.
31. Tóth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/ indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study. Am J Cardiovasc Drugs 2014; 14(2): 137– 145. doi: 10.1007/ s40256-014-0067-2.
32. Špinar J, Špinarová L, Vitovec J. Studie PIANIST – trojkombinace v lečbě hypertenze. Hypertenze & kardiovaskularni prevence 2015; 4: 20– 23.
33. Widimský J jr. První fixní trojkombinace – perindopril arginin-indapamid-amlodipin: nový přístup v kombinační léčbě hypertenze. Vnitř Lék 2014; 60(9): 801– 807.
34. Kociánová E. Fixní trojkombinace perindopril arginin/ indapamid/ amlodipin v léčbě arteriální hypertenze. Remedia 2014; 24(6): 516– 519.
35. Rosolová H. Význam fixní kombinace atorvastatin, perindopril a amlodipin (Lipertance). Farmakoterapie 2016; 12(4): 484– 489.
36. Widimský J jr. Lipertance® – první fixní trojkombinace atorvastatinu, perindopril argininu a amlodipinu. Hypertenze & kardiovaskularni prevence 2016; 5: 63– 67.
37. Špinar J, Vítovec J, Špinarová L. Lipertance – dva problémy, jedno řešení. Kardiol Rev Int Med 2016; 18(4): 287– 292.
Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology General practitioner for adultsArticle was published in
Cardiology Review
2018 Issue 3
Most read in this issue
- Perindopril and cardiovascular disease – 25 years of success in cardiology
- Hypothyroidism and the heart
- Gestational diabetes mellitus and possibilities for its treatment
- Commented shortened version of the 2018 ESC Guidelines for the diagnosis and management of syncope